Home > DNA/RNA Synthesis & > Nelarabine

Nelarabine

奈拉滨,奈拉宾,506U78

Nelarabine是嘌呤核苷酸类似物，为DNA合成抑制剂，对肿瘤细胞的IC50为0.067-2.15 μM，可作用于T细胞急性淋巴细胞白血病。

目录号
EY0617
EY0617
EY0617
EY0617
纯度
99.53%
99.53%
99.53%
99.53%
规格
1 mg
5 mg
10 mg
50 mg
原价
523
1020
2100
6800
售价
523
1020
2100
6800
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Nelarabine is a purine nucleoside analog and DNA synthesis inhibitor with IC50 from 0.067-2.15 μM in tumor cells.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0.125 μg/mL - 8 μg/mL

  • 动物实验

    35 mg/kg静脉注射给药

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Beesley AH, et al. Br J Haematol. 2007, 137(2), 109-116.
    [2] DeAngelo DJ, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42.

    分子式
    C11H15N5O5    		 分子量
    297.27    		 CAS号
    121032-29-9    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    60 mg/mL    		 Water
    3 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01094860 Leukemia Drug: Nelarabine M.D. Anderson Cancer Center|GlaxoSmithKline Phase 1 2010-06-01 2016-12-16
    NCT00866671 Leukaemia, Lymphoblastic, Acute Drug: nelarabine GlaxoSmithKline 2009-02-01 2015-01-12
    NCT01376115 Cancer Drug: Nelarabine Novartis 2008-01-01 2016-03-11
    NCT02763384 T-Acute Lymphoblastic Leukemia|Adult T Lymphoblastic Lymphoma Drug: BL-8040|Drug: Nelarabine Washington University School of Medicine Phase 2 2016-12-02 2017-02-02
    NCT00005080 Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Small Intestine Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome Drug: nelarabine National Cancer Institute (NCI) Phase 2 2000-05-01 2013-01-15
    NCT00684619 T-ALL, T-NHL (Lymphoblastic) Drug: Nelarabine Johann Wolfgang Goethe University Hospital Phase 2 2003-06-01 2010-08-20
    NCT00981799 Relapsed T-Cell Acute Lymphoblastic Leukemia|Relapsed T-Cell Lymphoblastic Lymphoma Drug: Nelarabine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Filgrastim Therapeutic Advances in Childhood Leukemia Consortium|GlaxoSmithKline|Novartis Phase 1|Phase 2 2010-06-01 2015-11-20
    NCT00501826 Leukemia|Lymphoblastic Lymphoma|Leukemia, Lymphoblastic, Acute Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Methotrexate|Drug: Vincristine|Drug: Nelarabine M.D. Anderson Cancer Center|Novartis Phase 2 2007-07-01 2017-03-23
    NCT00005982 Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome Drug: nelarabine|Other: pharmacological study National Cancer Institute (NCI) Phase 2 2000-04-01 2013-01-22
    NCT00005950 Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstr枚m Macroglobulinemia Drug: nelarabine National Cancer Institute (NCI) Phase 2 2000-04-01 2013-01-22
    NCT00406757 Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic|Lymphoblastic Lymphoma|Acute Lymphoblastic Leukemia Drug: Nelarabine injection 400mg/m2|Drug: Nelarabine injection 650mg/m2|Drug: Nelarabine injection 1000mg/m2|Drug: Nelarabine injection 1500mg/m2 GlaxoSmithKline Phase 1 2006-08-01 2012-05-31
    NCT02619630 T-cell Adult Acute Lymphoblastic Leukemia Drug: nelarabine Assistance Publique - H么pitaux de Paris Phase 2 2015-12-01 2016-06-23
    NCT00003545 Leukemia|Lymphoma Drug: nelarabine National Cancer Institute (NCI)|Southwest Oncology Group Phase 2 1998-08-01 2013-02-04
    NCT00004239 Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes Drug: Compound 506U78 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Phase 1 1999-12-01 2016-07-01
    NCT00003837 Leukemia|Lymphoma Drug: nelarabine National Cancer Institute (NCI) 1999-09-01 2013-06-18
    NCT00006020 Leukemia Drug: nelarabine Southwest Oncology Group|National Cancer Institute (NCI) Phase 2 2000-07-01 2015-03-05
    NCT00003635 Leukemia Drug: nelarabine GlaxoSmithKline|National Cancer Institute (NCI) Phase 2 1999-01-01 2013-07-17
    NCT00002970 Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Childhood Acute Lymphoblastic Leukemia Drug: nelarabine|Drug: methotrexate|Drug: cytarabine|Drug: therapeutic hydrocortisone National Cancer Institute (NCI)|Children's Cancer Group Phase 2 1997-06-01 2013-07-01
    NCT02881086 Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma Drug: Rituximab|Drug: Nelarabine|Drug: PEG-Asparaginase|Procedure: Cranial irradiation|Drug: Imatinib|Drug: Idarubicin|Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Vincristine|Drug: Mercaptopurine|Drug: VP16|Drug: Daunorubicin (DNR)|Drug: Methotrexate|Procedure: Stem cell transplantation|Drug: Cytarabine|Drug: Vindesine|Drug: Adriamycin|Drug: Prednisolone Johann Wolfgang Goethe University Hospital Phase 3 2016-08-01 2016-08-23
    NCT01085617 Leukemia|Mucositis|Oral Complications Biological: palifermin|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Drug: fludarabine phosphate|Drug: imatinib mesylate|Drug: melphalan|Drug: mercaptopurine|Drug: methotrexate|Drug: nelarabine|Drug: pegaspargase|Drug: vincristine sulfate|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: assessment of therapy complications|Radiation: total-body irradiation University College London Hospitals|National Cancer Institute (NCI) Phase 3 2010-01-01 2013-08-23
    NCT00408005 Adult T Acute Lymphoblastic Leukemia|Childhood T Acute Lymphoblastic Leukemia|Stage II Adult T-Cell Leukemia/Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Contiguous Adult Lymphoblastic Lymphoma|Stage II Non-Contiguous Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-Cell Leukemia/Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-Cell Leukemia/Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Drug: Asparaginase|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Nelarabine|Drug: Pegaspargase|Drug: Prednisone|Radiation: Radiation Therapy|Drug: Thioguanine|Drug: Vincristine Sulfate National Cancer Institute (NCI) Phase 3 2007-01-01 2017-03-14

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：